UCB presentation. October 2014

(1)

UCB presentation

(2)

Disclaimer and safe harbor

Forward-looking statements:

This presentation contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this presentation. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product

candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this presentation and expressly disclaims any duty to update any information contained in this presentation, either to confirm the actual results or to report a change in its expectations. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

(3)

Focus:

Central Nervous System & Immunology

R&D expenses 2013:

25% of € 3.4 billion revenue

Over 584 000 patients treated with UCB’s

core medicines, “CVN”

Operations in more than 40 countries

Approximately 8 700 employees globally

Inspired by

patients.

(4)

UCB’s growth prospects confirmed

Mature product portfolio

Emerging markets

Cimzia®, Vimpat®, Neupro®

S

u

p

e

ri

o

r

a

n

d

s

u

s

ta

in

a

b

le

v

a

lu

e

Schematic picture

(5)

9 months key financial highlights

FY 2014 financial outlook confirmed

€ million 9M 2014 9M 2013 Actual Constant

Revenue

2 647

2 499

6% 8%

Net sales CVN

1 044

847

23% 26%

Cimzia

®

₅₆₁

₄₂₃

_32% _36%

Vimpat

®

₃₃₅

₂₉₄

_14% _17%

Neupro

®

₁₄₈

₁₃₀

_15% _15%

Keppra

®

₅₀₄

₅₃₂

_-5% _-3%

FY 2014 outlook confirmed

Revenue

~

€ 3.5 – 3.6 billion

REBITDA

~

€ 740 - 770 million

Core EPS

€ 1.90 -2.05

(6)

UCB’s five strategic growth priorities (9M 2014)

Continuing our growth path

1 Constant exchange rate

2 Brazil, Russia, India, China, Mexico and Turkey 3 Partial-onset seizures

ן

1

. Grow Cimzia

®

, Vimpat

®

and Neupro

®

• “CVN” combined sales: € 1 044 million (+23%; +26% CER1₎

• Vimpat®_{monotherapy approval in the U.S.}

ן

2.

Build emerging markets and Japan

• Emerging markets2_{-3% (+5% CER); Japan -6% (+1% CER)}

ן

3.

Advance UCB’s rich late-stage pipeline

• Positive topline Phase 3 results for brivaracetam in epilepsy POS3 _patients

ן

4.

Deliver breakthrough medicines to the clinic

• Two molecules moving to Phase 2; one molecule entered Phase 1

ן

5.

Reach competitive profitability

(7)

• Rheumatoid arthritis (RA)

• Psoriatic arthritis (PsA)

• Ankylosing spondylitis (AS)

• Crohn’s disease (CD)

• Psoriatic arthritis (PsA)

• Axial spondyloarthritis (incl. AS)

1 Brazil, Russia, India, China, Mexico and Turkey

Cimzia®_{available to patients in 54 countries, including Brazil, Russia, Mexico & Turkey}

Numbers may not add due to rounding

€ million 9M 2014 9M 2013 Actual CER

North America

345

271

27% 31%

Europe

168

120

40% 40%

Japan

24

14

76% 94%

Emerging markets

1

₄

_-9% _-1%

Rest of the World

19

14

32% 37%

Total Cimzia

®

₅₆₁

₄₂₃

_32% _36%

Cimzia

®

performance

Reaching more patients

(8)

3.0% 3.2% 3.4% 3.6% 3.8% 4.0%

Aug'13 Oct'13 Dec'13 Feb'14 Apr'14 Jun'14 Aug'14

Cimzia

®

in-market performance (August 2014)

3.4% 5.3% 11.9% 0% 2% 4% 6% 8% 10% 12% 14%

Anti-TNF All Biologics Cimzia

U.S. - Cimzia®_{rheumatology growth}

6.0% 7.0% 8.0% 9.0% 10.0% 11.0%

EU - Cimzia®_{RA – R3M Patient Share}

8.1% 15.6% 38.5% 0% 5% 10% 15% 20% 25% 30% 35% 40% 45%

Anti-TNF All Biologics Cimzia

EU - Cimzia®_{RA growth}

• In-Market growth and share based on TRx

• Shares calculated based on Anti-TNF market

• In-market growth is calculated for MAT Aug ’14 vs. MAT Aug ’13 • Market share is calculated for R3M

Aug ’14

• In-Market growth and share based on Exit Patients • Shares calculated based on RA

Anti-TNF market

• In-market growth is calculated for Aug ’14 vs. Aug ’13 • Market share is calculated for

R3M Aug ’14

U.S.

EU

Rheumatology includes: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PSA), Axial Spondyloarthritis (AxSpA), and Ankylosing Spondylitis (AS) Source EU - IMS MIDAS + local UK HMSL data

Source US - US IMS NPA data

U.S. - Cimzia®_{Rheumatology – R3M TRx Share}

Patient market share

9.9%

TRx market share 3.8%

(9)

North America

243

224

9% 12%

Europe

81

64

27% 27%

Emerging markets

1

₄

₂

_68% _80%

Rest of the World

7

4

59% 67%

Total Vimpat

®

₃₃₅

₂₉₄

_14% _17%

Vimpat

®

performance

Monotherapy in the U.S. launched in September

1 Brazil, Russia, India, China, Mexico and Turkey 2 Partial-onset seizures

3 Primary general tonic clonic seizures

Vimpat®_{available to patients in 43 countries, including Russia, India & Mexico}

Epilepsy POS2

Epilepsy PGTCS3

Ped. adj. therapy 2017

Monotherapy (U.S.) Oct. 2013

Phase 2 Phase 3 Filing

Monotherapy (EU) Q4 2014 Adj. therapy (Asia)

H1 2015

Adj. therapy Start early 2015

(10)

Vimpat

®

in-market performance (August 2014)

• In-Market growth and share based on TRx

• In-market growth is calculated for MAT Aug ’14 vs. MAT Aug ’13 • Market share is calculated for

R3M Aug ’14

• In-Market growth and share based on TDx

• In-market growth is calculated for MAT Aug ’14 vs. MAT Aug ’13 • Market share is calculated for

R3M Aug ’14

U.S.

EU

Source EU - IMS MIDAS Source US - US IMS NPA data

4.4% 19.6% 0% 5% 10% 15% 20% 25% Market Vimpat

U.S. - Vimpat®_growth

TRx market share 3.1% 2.6% 2.7% 2.8% 2.9% 3.0% 3.1% 3.2%

U.S. - Vimpat®_{- R3M TRx Share}

-1.3% 23.8% -5% 0% 5% 10% 15% 20% 25% 30% Market Vimpat EU - Vimpat®_growth TDx market share 2.1% 1.5% 1.6% 1.7% 1.8% 1.9% 2.0% 2.1%

(11)

Neupro

®

performance

North America

30

28

9% 12%

Europe

102

94

8% 8%

Japan

12

5

>100% >100%

Emerging markets

1

₁

_8% _16%

Rest of the World

3

2

87% 91%

Total Neupro

®

₁₄₈

₁₃₀

_15% _15%

On-going performance

Neupro®_{available in 46 countries, including Russia & Mexico}

Numbers may not add due to rounding

• Parkinson’s disease (PD)

(12)

Neupro

®

in-market performance (August 2014)

• In-market growth and share based on TRx

• Shares calculated based on PD Key Competitors markets • In-market growth is calculated for

Current R6M vs. Previous R6M • In-market share is calculated for

R3M Aug ’14

• In-market growth and share based on TDx

• Shares calculated based on PD Key Competitors markets • In-market growth is calculated for

MAT Aug ’14 vs. MAT Aug ’13 • Market share is calculated for

R3M Aug ’14

U.S.

EU

Parkinson’s Disease (PD) Source EU - IMS MIDAS Source US - US IMS NPA data

1.5% 1.5% 3.5% 0% 5% 10% 15% 20%

Market Competitors Neupro

U.S. - Neupro®_{PD growth}

TRx market share 6.5% 2.6% 1.6% 12.2% 0% 5% 10% 15% 20%

Market Competitors Neupro

EU - Neupro®_{PD growth} TDx market share 15.1% 5.0% 5.5% 6.0% 6.5% 7.0%

U.S. - Neupro®_{PD – R3M TRx Share}

13.0% 14.0% 15.0% 16.0%

(13)

UCB delivers growth

Core medicines tracking well towards peak sales targets

Expected peak sales at least € 1.5 billion

1

Inflammatory arthritis indications and Crohn’s disease ■ Total net sales of € 561 million (+32%)

Expected peak sales at least € 1.2 billion

1

Epilepsy partial onset seizures

■ Total net sales of € 335 million (+14%)

■ Monotherapy approved & launched in the U.S.

Expected peak sales at least € 400 million

1

Parkinson’s disease and restless legs syndrome ■ Total net sales of € 148 million (+15%)

Combined expected CVN peak sales at least € 3.1 billion

1

(14)

Keppra

®

performances

Status of exclusivity:

• Japan - exclusivity until 2018

• U.S. - expired November 2008 (Keppra®_{XR - September 2011)} • Europe - expired September 2010

North America

151

165

-8% -5%

Europe

204

237

-14% -14%

Japan

53

42

25% 38%

Emerging markets

1

₆₈

₅₇

_20% _29%

Rest of the World

28

31

-9% -8%

Total Keppra

®

₅₀₄

₅₃₂

_-5% _-3%

Sizeable franchise

Sizeable franchise going forward!

(15)

UCB: Building emerging markets and Japan

FX headwind and a specialty focus

*Brazil, Russia, India, China, Mexico, Turkey

Emerging markets*

• Net sales 9M 2014: -3% (+5% CER)

• Keppra®_{: € 68 million (+20%; +29% CER)}

• Agreement with Biogen Idec to develop and commercialize multiple sclerosis and hemophilia therapies in Asia

UCB Japan

• Net sales 9M2014: -6 % (+1% CER)

• E Keppra®_{: € 53 million (+25 %; +38% CER)}

(16)

brivaracetam

epilepsy POS1_{/ adj. therapy}

epratuzumab

systemic lupus erythematosus

romosozumab

osteoporosis in postmenopausal women

romosozumab

osteoporosis in men UCB4940 (IL17)

psoriatic arthritis Phase 2 results: H2 2015

UCB5857 (PI3K Delta inhibitor)

immunological diseases Phase 2 start: early 2015 CDP7657 (CD40L antibody)

systemic lupus erythematosus

Phase 1 results: H2 2014

(Partner: Biogen Idec) UCB7665

immunological diseases

UCB's development pipeline

Phase 3 results: H1 2015 (Partner: Immunomedics)

Phase 3 results: H1 2016 (Partner: Amgen)

Phase 1 Phase 2 Phase 3 Filing

Pipeline filled with new molecular entities

1 Partial onset seizures

Submission: early 2015

Phase 3 results: H2 2016 (Partner: Amgen)

(17)

UCB’s promising early pipeline

Early pipeline holds breakthrough potential

Discovery:

• Breakthrough innovation collaboration with Sanofi

• Discovery and development of innovative anti-inflammatory small molecules • Selected biologic agents to be replaced with small molecules

• Potentially treating a wide range of immune-mediated diseases

Two Phase 1 compounds (NBEs) with significant differentiation potential:

• CDP7657 (anti-CD40L) in systemic lupus erythematosus first results in H2 2014 • UCB7665, immunological diseases

UCB5857 (PI3K

Δ) successfully passed a Phase 1 study

• Phase 2 to start early 2015

UCB4940 (IL17) for psoriatic arthritis moved into Phase 2

• First results in H2 2015

NBE: new biological entity NCE: new chemical entity

(18)

2014 financial outlook confirmed

Full year 2014 expected dynamics

Financial outlook 2014*

Revenue

~

€ 3.5 - 3.6 billion

• Cimzia®_{, Vimpat}®_{, Neupro}®_growth

Recurring

EBITDA

~

€ 740 - 770 million

• Strong early and late-stage pipeline • Continued cost efficiencies

Core EPS

~

€ 1.90 - € 2.05

• ~192 million shares

*considers application of IFRS10

EBITDA: Earning before interests, taxes, depreciation and amortization charges EPS: Earnings per share

(19)

(20)

UCB: reinventing itself, leveraging a solid heritage

to deliver sustainable and superior value for patients

1928 1980s 1990s 2004 2006 2008-2012 Today

Chemical Group Primary Care Pharma Specialty Bio-Pharma

Focus: CNS + immunology 1936 1928: Emmanuel Janssen establishes UCB in Brussels 1990s: approval of Keppra®_, a novel anti-epileptic 2006: UCB acquires German pharma company Schwarz Pharma Launch of new medicines 2004: UCB acquires British biotech company Celltech 1980s: UCB registers

its novel antihistamine Zyrtec®

1936: UCB enters the United States

2005

2005: UCB divests non-pharma business

(21)

UCB HY 2014 financial highlights

EBITDA: Earning before interests, taxes, depreciation and amortization charges CER: Constant Exchange Rate

CER +10% -4% +40% +29% Actual

Good top-line performance driving growth

Revenue

• Continued sales growth of core medicines

• Adverse exchange rate impacts

€ 1 757 million

Total operating expenses

• Continuous improvement and constantly striving for improved resource allocation

• 9% lower marketing & selling expenses

• Stable research & development expenses

€ 920 million

Recurring EBITDA

€ 391 million

Net profit

• 30% tax rate

€ 113 million

Core earnings per share

(Based on 191 million weighted average shares outstanding)

€ 1.22

+6%

+66% +100% -2%

(22)

0 100 200 300 400 Cimzia® Vimpat® Neupro® Keppra® Zyrtec® Metadate™ CD Xyzal® Nootropil® omeprazole Other € million

HY 2014 net sales

€ 1 562 million (+7%; +11% CER)

Cor e m e d ici n e s M a tur e pr oduc ts

HY 2013 net sales HY 2014 net sales

Total core products sales € 672 million (+25%; +29% CER)

Total mature products sales € 890 million (-4%; 0% CER)

Keppra®_{net sales include Keppra}®_{XR and AG net sales}

Zyrtec®_{net sales include Zyrtec-D}®_{and Cirrus}®_{net sales}

(23)

Recurring EBITDA

Growth despite FX headwinds

€ million HY 2014 HY 2013 Variance

Actual (restated)1 _Actual _CER

Revenue 1 757 1 657 6% 10%

Net sales 1 562 1 466 7% 11%

Royalty income and fees 81 85 -5% -6%

Other revenue 114 106 8% 9%

Gross profit 1 195 1 139 5% 10%

Marketing and selling expenses -375 -413 9% 5%

R&D expenses -446 -444 0% -2%

G&A expenses -102 -107 5% 3%

Other operating income 2 3 -7% -8%

Total operating expenses -920 -961 4% 2%

Recurring EBIT 274 178 54% 74%

Amortization of intangible assets 84 94 -11% -11%

Depreciation charges 33 31 4% 5%

Recurring EBITDA 391 303 29% 40%

1 Restatement related to IFRS 10 EBIT: Earnings before interest and taxes

(24)

Net profit

Actual (restated)1 _Actual _CER

Recurring EBIT 274 178 54% 74%

Impairment charges -26 -8 >-100% >-100%

Restructuring expenses -14 -11 -28% -30%

Gain on disposals 11 8 19% 14%

Other non-recurring income -18 -8 >-100% >-100%

Total non-recurring income / expenses (-) -47 -19 >-100% >-100%

EBIT 227 159 43% 64%

Net financial expenses -67 -72 7% 6%

Income tax expenses (-) / credit -48 -22 >-100% >-100%

Profit from continuing operations 112 65 71% >-100%

Net profit 113 68 66% 100%

Attributable to UCB shareholders 137 59 >100% >100% Attributable to non-controlling interests -24 9 >-100% >-100%

1 Restatement related to IFRS 10 EBIT: Earnings before interest and taxes

(25)

Core earnings per share

Actual (restated)1 _Actual _CER Net profit attributable to UCB

shareholders 137 59 >100% >100%

+ After-tax non-recurring items and

financial one-offs 46 14 >100% >100%

- Profit / loss (-) from discontinued

operations -1 -3 58% 58%

+ After-tax amortization of intangibles 51 57 -11% -10%

Core net profit 233 127 84% >100%

Weighted average number of shares (mn) 191 182 5% N/A

Core EPS € 1.22 € 0.70 75% 92%

(26)

640 84 40 574 250 176 500 75 350 3001 150 100 Liquid assets 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 beyond

Belgian Commercial Paper Belgian retail bond Institutional eurobond Perpetual bond EIB loan

Debt maturity schedule

(@ 30 June 2014)

Convertible bond early redeemed in March

1 Perpetual bond with first call date in March 2016, recognized as equity on UCB’s balance sheet 658

800

225

350

(27)

HY 2014 net debt walk

-2,000 -1,729 281 (107) (91) (175) ₍₂₄₎ 387 Net debt @ 01.01.2014 CF from Operations

Taxes paid Capex Dividends & Treasury share

issuance

Net interest FX, Convertible bond, and other

Net debt @ 30.06.2014 € million

Change in net debt: + 271 m

1 Includes: foreign exchange fluctuations, cash from discontinued operations, change in bank overdraft, available for sale debt security, non-cash portion of borrowings, and net proceeds / (loss from disposals)

(28)

North America 43% France 5% Germany 7% Italy 5% Spain 4% U.K. & Ireland 4% Europe others 11% Japan 7% Emerging markets 10% RoW + unallocated 4%

Europe

36%

HY 2014 net sales : € 1 562 million

Geographic and therapeutic breakdown

Cimzia® 353 23% Immunology -Allergy 141 9% Other 333 21% CNS - other 77 5% Keppra® 339 22% Neupro® 102 6% Vimpat® 217 14%

(29)

G&A 9% Marketing & Sales 52% R&D 13% Manufacturing 26%

Workforce distribution

Total headcount @ 30 June 2014: 8 851 employees

Employees by region Employees by function Belgium 22% France 1% Germany 8% Italy 1% UK & Ireland 8% Spain 1% Europe -Others 7% North America 20% Emerging market 26% Japan 4% Rest of the World 2%

(30)

Upcoming expected R&D milestones

2014

2017

epratuzumab SLE Phase 3 results Cimzia® Juvenile IA Phase 3 results romosozumab osteoporosis in post-menopausal women Phase 3 results Cimzia® C-Early™ results Cimzia® Exxelerate™ results Vimpat® epilepsy POS - adj. ther. (Asia) -

Phase 3 results Vimpat® _epilepsy

POS - mono – Phase 3 results

CNS Immunology

axSpA / AS: axial spondyloarthritis / ankylosing spondylitis IA: Idiopathic arthritis POS: Partial onset seizures SLE: Systemic lupus erythematosus PMO: Post-menopausal osteoporosis

Vimpat®

epilepsy POS - ped. adj. ther. - Phase 3 results Vimpat® PGTCS - adj. therapy - Phase 3 start CDP7657 SLE Phase 1 results UCB5857 immunology Phase 2 start brivaracetam epilepsy POS - adj. therapy submission romosozumab osteoporosis in men Phase 3 results UCB4940 psoriatic arthritis Phase 2 results

2016

2015

Vimpat® _epilepsy POS - mono Cimzia® psoriasis Phase 3 start

(31)

UCB's development pipeline

Life cycle management

Phase 2 Phase 3 Filing

AxSpA3_(U.S.) Feb. 2013 Juvenile IA H1 2016 Eloctate™ Multiple sclerosis daclizumab Hemophilia A Hemophilia B Alprolix™ Tecfidera® Tysabri® Plegridy™

For development in PR China

(In-licensed from Biogen Idec)

1 Partial onset seizures

2 Primary generalized tonic-clonic seizures 3 Axial Spondyloarthritis Exxelerate™ H2 2016 C-Early™ H1 2016 Epilepsy POS1 Epilepsy PGTCS2

Ped. adj. therapy 2017

Monotherapy (U.S.) Oct. 2013

Monotherapy (EU)

Q4 2014 Adj. therapy (Asia)

H1 2015

Adj. therapy Start early 2015

Psoriasis H1 2015

(32)

Lyophilized formulation accounts for approx.

20% of U.S. Cimzia®_{sales measured in IMS}

dollarized sales

Cimzia

®

offers 2 unique solutions for the U.S. market

Consistent and continued growth of prefilled

syringe as measured in IMS dollarized sales

Lyophilized formulation and prefilled syringe

$35 $38 $47 $55 $70 H1 2012 H2 2012 H1 2013 H2 2013 H1 2014 Rapid acceleration over the last 6

months +10% +23% +17% +27% $163 $188 $206 $226 $283 H1 2012 H2 2012 H1 2013 H2 2013 H1 2014 +15% +10% +10% +25%

(33)

29 32 37 38

114 118

122 125

Jan-12 Jan-13 Jan-14 Jul-14

Access to Cimzia

®

in the U.S.

Lives in preferred or co-preferred position

C o v er ed liv e s in m illio n s

Total lives with Cimzia®₍_{certolizumab pegol}_{) in preferred or co-preferred position in the U.S.}

Source: Preferred lives from UCB Internal Contracts Database, co-preferred from UCB internal analysis.

159 163

150 143

(34)

Phase 3 Filing Launch

Japan U.S.

Crohn’s disease (CD)

Ankylosing spondylitis (AS)

EU

Cimzia

®

path to at least € 1.5 billion peak sales

Juvenile IA (JIA)

Exxelerate™ H2 2016

C-Early™ H1 2016 Rheumatoid arthritis (RA)

Psoriatic arthritis (PsA)

Axial spondyloarthritis (AxSpA)

May 2009 Oct 2009 Mar 2013

Oct 2013 Apr 2008 Sep 2013 Nov 2013 Results H1 2016 Oct 2013 Oct 2013 Psoriasis (Ps) U.S. Feb 2013 Start H1 2015

(35)

Monotherapy

Adjunctive therapy

EU Japan

U.S.

Vimpat

®

path to at least € 1.2 billion peak sales

Asia

H1 2015

May 2009 Sep 2008 EU Q4 2014 Pediatric 2017 Adjunctive therapy Epilepsy PGTCS² Epilepsy POS1

2 Primary generalized tonic-clonic seizures

Phase 3

Start early 2015

(36)

Early stage

EU Japan

U.S.

Neupro

®

path to at least € 400 million peak sales

May 2009 Feb 2006

Advanced stage

Parkinson’s disease (PD)

2 Primary generalized tonic-clonic seizures

Restless legs syndrome (RLS) Jan 2007 Jun 2009 Jul 2012 Jul 2012 Feb 2013 Feb 2013 Feb 2013

(37)

Brivaracetam clinical development path

A potential new option for people living with epilepsy

Phase 1

30 studies

completed

Phase 2 & 3

7 studies

ongoing

10 studies

completed

(adults and children with focal and generalized epilepsy)

4 studies

completed in

other

indications

Exposure

• > 3 000 people exposed

in completed Phase 2 / 3 studies

• ~ 6 000 patient years

of exposure

• Some patients for

> 8 years

(38)

Brivaracetam Phase 3 development program

New treatment option for patients with uncontrolled seizures

* Statistically significant

1 274 patients

(aged 16-70) Efficacy + safety 12 weeks N01252 N01253 Tolerability + safety 16 weeks N01254

768 patients

(aged 16-80) Efficacy + safety 12 weeks N01358

*

_*

placebo, 20, 50, 100 mg/day Europe + India placebo, 5, 20, 50 mg/day

North / South America + Australia

flexible placebo, 100, 200 mg/day

(fixed dose, no titration)

U.S. + Europe + RoW (27 countries) Dosing Duration Primary endpoints Region

(39)

Positive Topline Results: Submission early 2015

Seizure reduction in treatment resistant patients

High unmet medical need in ~1/3 of treated epilepsy patients

• One of the largest Phase 3 programs seen in epilepsy

• 50% of particiants were resistant to 5+ AEDs

• Statistically significant and clinically relevant top-line results

• Seizure freedom observed

• Safety in line with previous studies*

• Presentation at upcoming epilepsy congresses

• Submissionto U.S. and EU authorities planned for early 2015

Key characteristics and headline results

AED: Anti-epileptic Drug

*The most commonly reported adverse events were somnolence, dizziness, fatigue and headache. Source: UCB data on file

25-30% 50% 20-25% Controlled on 1st monotherapy Uncontrolled despite 2-3 AEDs Controlled on more than 1 AED

(40)

Shareholder structure

(September 2014)

“Free float” investors by region

Stable shareholder base with free-float of 64%

Total number of shares: 194.5 million

Weighted average shares outstanding: 192 million

(41)

ן

Antje Witte, Vice President Investor Relations

• Phone: +32 2 559 9414 • E-mail: [email protected]

ן

Alexandra Deschner, Investor Relations Director

• Phone: +32 2 559 9683

• E-mail: [email protected]

ן

Isabelle Ghellynck, Investor Relations Manager

• Phone: +32 2 559 9588

ן

Nathalie Deldime, Investor Relations Events Manager

• Phone: +32 2 559 9291

UCB presentation. October 2014